MAMandy Aldwin-Easton

Mandy Aldwin-Easton

*This is an algorithmically generated author record based on publicly available information.

Mandy Aldwin-Easton has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A national epidemiological study of inherited ichthyoses in England from 1998 to 2024

    by Mark D Eisner, Maisie Blyth, Jennifer M Broughan, Corinne Mallinson, Lizz Paley, Jeanette Aston, Sally Vernon, Steven Hardy, Shehnaz Ahmed, Mandy Aldwin-Easton, et al.

    Background: Ichthyoses (epidermal differentiation disorders) cause significant morbidity and mortality; however, national epidemiological data that link diagnoses of ichthyoses with systemic comorbidities are lacking. Objectives: To report epidemiological data on inherited ichthyoses in England, together with patient-level comorbidities and genetic testing status. Methods: This national retrospective cohort study identified ichthyosis case records from healthcare databases in England, using International Classification of Diseases, 10th Revision (ICD-10) codes from 1998 to 2024. Cohort demographics, comorbidities, genetic testing data and mortality data were extracted from routinely collected National Health Service data. Results: We identified 4330 patients with ichthyosis, of whom 3758 were categorized as having a rare ichthyosis. The prevalence of rare ichthyoses was 51.6 per million (95% confidence interval 49.7–53.5). Compared with the reference population, the overall cohort was younger [median age 22 (interquartile range 11–49) vs. 41 years], more likely to identify as Asian (17.1% vs. 9.6%; P < 0.001) and were more frequently in the most deprived quintiles (48.1% vs. 40.0%; P < 0.001). The rates of comorbidities, including asthma, inflammatory arthropathies and atrial fibrillation, were higher than in the reference population. Nineteen per cent of deaths occurred before the age of 25 years compared with 1% of deaths at this age threshold in the reference population (P < 0.001). Genetic testing data revealed a low proportion of tested cases; pathogenic variants in genes known to cause ichthyosis were found in 56.3% of the tested cases (n = 90/160). Conclusions: We report an increased range of comorbidities in patients living with rare ichthyoses, highlighting the systemic burden in patients categorized as having nonsyndromic ichthyosis. These data inform healthcare planning, research design and the redressing of inequities of care. An author video to accompany this article is available online.


  • The Importance of Shared Patient Voices in Advancing Science for Genodermatoses on a Global Scale

    by Fauve C.A.P. van Veen, Eli Sprecher, Janice Schwartz, Tom Baker, Edel A. O’TOole, Karin Veldman, Mandy Aldwin-Easton, Antoine Gliksohn, Ncoza Dlova, Fernando Larcher, et al.


  • Top Cited Papers
    Open Access

    Nonsyndromic epidermal differentiation disorders: a new classification toward pathogenesis-based therapy

    by Masashi Akiyama, Keith Choate, Ángela Hernández-Martín, Mandy Aldwin-Easton, Christine Bodemer, Antoni Gostyński, Alain Hovnanian, Akemi Ishida-Yamamoto, Kiril Malovitski, Edel A O’tOole, et al.

    Epidermal differentiation disorders (EDDs) encompass inherited conditions characterized by abnormal epidermal differentiation, including nonsyndromic and syndromic subtypes with more extensive cutaneous involvement or palmoplantar keratoderma. Nonsyndromic EDDs (nEDDs) are defined as disorders that primarily affect large areas of skin and adnexal structures without alterations in extracutaneous tissues resulting from the underlying genetic change. To facilitate the development of targeted therapies and to provide clinicians with clearer therapeutic guidance, we have developed a new nomenclature for EDDs that includes the causative altered gene and the nEDD subgroup designation, sometimes with a clinical or histological descriptor or acronym. Historically, many nEDDs have been named on the basis of phenotypic characteristics or associations that are now considered outdated or inappropriate. For example, the term ‘harlequin ichthyosis’ evokes potentially stigmatizing images. Similarly, the word ‘ichthyosis’ is derived from the Greek ichthys, meaning fish, and the Greek hystrix, meaning porcupine, further emphasizing the need to abandon derogatory terminology. As a result, the clinical relevance of the previous classification, which included eponymous and/or descriptive titles, has diminished. In the new, gene-based classification, old terms considered pejorative, such as ichthyosis, vulgaris, hystrix and harlequin have been eliminated and eponyms have been replaced. Among the 53 genetically distinct nEDDs are conditions formerly known as autosomal recessive congenital ichthyosis, erythrokeratodermia variabilis et progressiva, Hailey–Hailey disease and Darier–White disease. This review outlines the updated nomenclature and classifications of nEDDs, linked to detailed clinical descriptions and representative photographs to guide practitioners.


  • Top Cited Papers
    Open Access

    Syndromic epidermal differentiation disorders: a new classification toward pathogenesis-based therapy

    by Amy S Paller, Joyce Teng, Juliette Mazereeuw-Hautier, Ángela Hernández-Martín, Céline Granier Tournier, Alain Hovnanian, Mandy Aldwin-Easton, Gianluca Tadini, Janice Schwartz, Eli Sprecher, et al.

    Since the 2010 classification of ichthyoses, our understanding of hereditary epidermal differentiation disorders (EDDs) has markedly increased, allowing for consideration of new therapeutic targets based on disease pathogenesis. A new gene- and protein product function-based classification focuses on shared mechanisms of disease pathogenesis, with the possibility that grouped disorders may respond similarly to new therapeutics. These EDDs have been subdivided into syndromic (sEDD), nonsyndromic with features limited to skin and appendages, and predominantly palmoplantar skin involvement (nonsyndromic and syndromic). sEDDs have clinically important extracutaneous features related to the gene alteration. Often, recognition based on skin manifestations facilitates early gene-based diagnosis, discussion of prognosis, genetic counselling and the initiation of therapy. All sEDDs are rare; the most common are STS-sEDD (formerly known as X-linked ichthyosis) and SPINK5-sEDD (formerly known as Netherton syndrome). Given the rarity, frequent association with early demise and variable clinical features of sEDDs, the natural history of the diseases with advancing age and genotype–phenotype relationships are poorly defined. Of the 51 sEDDs, associated neurological (n = 36; 71%) and/or ophthalmological (n = 25; 49%) findings are most common, and 39% (n = 20) have associated hair abnormalities. The widespread use of topical lovastatin for cholesterol synthesis-related sEDDs represents the prototype of pathogenesis-based therapy. This concept of upstream inhibition to prevent metabolite accumulation and supplementation with the pathway end product potentially applies to other sEDDs, such as those affecting ceramide synthesis and transport. Topical or systemically administered inhibition of activated pathways is another potential approach, exemplified by the emerging treatment of SPINK5-sEDD with kallikrein inhibitors. Many sEDDs may be amenable to gene editing or the introduction of functional cDNA. However, even systemic treatments targeting cutaneous diseases may not address extracutaneous manifestations that arise during embryological development.